Topical erythromycin v clindamycin therapy for acne. A multicenter, double-blind comparison.
The efficacy and safety of topical 1.5% erythromycin solution and 1% clindamycin phosphate solution were compared in the treatment of acne. The number of inflammatory lesions was significantly reduced at 12 weeks by 62% and 59% and the number of noninflammatory lesions by 43% and 39% in the erythromycin and clindamycin groups, respectively. The reduction in lesions was also reflected in the clinical evaluation of the overall facial condition; 73% of the 74 patients treated with erythromycin solution and 62% of the 80 patients treated with clindamycin solution had excellent or good responses at 12 weeks. The results of this study show that topically applied 1.5% erythromycin and 1.0% clindamycin solutions are both effective and comparable in reducing the clinical manifestation of acne in patients with moderate disease.
D000152:Acne Vulgaris / Q000188:drug therapy*; D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D002648:Child; D002981:Clindamycin / Q000008:administration & dosage* / Q000009:adverse effects; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D004917:Erythromycin / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D008297:Male; D008548:Melanosis / Q000139:chemically induced; D008875:Middle Aged; D009096:Multi-Institutional Systems; D010292:Paresthesia / Q000139:chemically induced; D013997:Time Factors
D002981:Clindamycin; D004917:Erythromycin